ESC 365 - Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.

ACVC Premium Access

Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.

Session: Live Abstract session - Antithrombotics and bleeding

Topic: Cardiovascular Pharmacotherapy

Speaker: Doctor H. Wang (Beijing, CN)

Event: ACVC 2021

Congress Presentation

Add to my library

About the speaker

Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

0 follower

7 more presentations in this session

Trends in major bleeding events in patients with acute coronary syndrome.

Speaker: Doctor A. Cordero (Elche, ES)

Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis

Speaker: Ms A. Abdul Razzack (Vijayawada, IN)

Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis

Speaker: Ms A. Abdul Razzack (Vijayawada, IN)

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

Speaker: Doctor H. Wang (Beijing, CN)

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

Speaker: Doctor H. Wang (Beijing, CN)

Access the full session

Live Abstract session - Antithrombotics and bleeding

Speakers: Doctor H. Wang, Doctor A. Cordero, Ms A. Abdul Razzack, Ms A. Abdul Razzack, Doctor H. Wang...

About the event

ACVC 2021

13 March - 14 March 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources